Just in Time Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Just in Time
| Protocol | EAY191-N4 [JIT] |
|---|---|
| Cancer Type: | Gynecologic |
A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS- A ComboMATCH Treatment Trial
| Protocol | EAY191-N5 [JIT] |
|---|---|
| Cancer Type: | Gynecologic |
EAY191-N5: A RANDOMIZED TRIAL OF NERATINIB, A PAN-ERBB INHIBITOR, ALONE OR IN COMBINATION WITH PALBOCICLIB, A CDK4/6 INHIBITOR, IN PATIENTS WITH HER2+ GYNECOLOGIC CANCERS AND OTHER SOLID TUMORS
A ComboMATCH Treatment Trial
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA7222 [JIT] |
|---|---|
| Cancer Type: | Sarcoma |
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY191 - A6 |
|---|---|
| Cancer Type: | Rare Cancer |
A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A032302 |
|---|---|
| Cancer Type: | Prostate Cancer |
A032302: Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
| Protocol | EA8231 [JIT] |
|---|---|
| Cancer Type: | Anti-PD(L)1-Resistant Advanced Urothelial Cancer |
A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | NRG HN010 |
|---|---|
| Cancer Type: | RARE |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1900K |
|---|---|
| Cancer Type: | NSCLC |
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
| Protocol | Alliance A092001 |
|---|---|
| Cancer Type: | Mesothelioma |
PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
| Protocol | SWOG S1900G |
|---|---|
| Cancer Type: | NSCLC |
A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
| Protocol | SWOG S1800E |
|---|---|
| Cancer Type: | NSCLC |
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
(Lung-MAP Non-Matched Sub-Study)
| Protocol | SWOG S1900J |
|---|---|
| Cancer Type: | NSCLC |
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
| Protocol | S1900J |
|---|---|
| Cancer Type: | NSCLC |
S1900J, “A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY191-S3 [JIT] |
|---|---|
| Cancer Type: | Non Breast |
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors
| Protocol | EAY191-E5 [JIT] |
|---|---|
| Cancer Type: | Multisite |
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
